TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06632405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab 200mg (3mg/kg for patient whose weight is below 50kg) will be administered as an intravenous infusion over 30 minutes every three weeks until unacceptable toxic effects or disease progression or other termination criteria appeared.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Camrelizumab
Description: Camrelizumab 200mg (3mg/kg for patient whose weight is below 50kg) will be administered as an intravenous infusion over 30 minutes every three weeks until unacceptable toxic effects or disease progression or other termination criteria appeared.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab paclitaxel 100mg/m2 will be administered as an intravenous infusion every 4 weeks in d1,8,15until unacceptable toxic effects or disease progression or other termination criteria appeared.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nab paclitaxel
Description: Nab paclitaxel 100mg/m2 will be administered as an intravenous infusion every 4 weeks in d1,8,15until unacceptable toxic effects or disease progression or other termination criteria appeared.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine Hydrochloride
Description: 5mg daily, start 3 days before the 1st administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5mg daily, start 3 days before the 1st administration
Study: NCT06634290

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intramedullary nailing augmentation
Description: Treatment of pertrochanteric hip fractures with intramedullary nailing with cephalic augmentation with bone cement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intramedullary nailing
Description: Treatment of pertrochanteric hip fractures with intramedullary nailing without cephalic augmentation
Study: NCT06032455

Intervention type: BEHAVIORAL
Intervention: Multisystemic therapy
Description: Multisystemic Therapy (MST) is an intensive, evidence-based treatment aimed at preventing out-of-home placement of adolescents with severe behavioural problems. The intervention is home-based and focuses not only on the adolescent, but also on the various systems surrounding the adolescent, such as the family, neighbourhood, school, and friends. MST helps parents increase their parenting competencies such as parental monitoring and find (more) social support in their environment. MST also helps adolescents improve their relationship with their parents, school participation, and social activities, and promotes contact with pro-social peers. These goals are achieved by working together with key figures in the family's environment. MST treatment duration is three to five months. In MST, a family can contact a therapist 24/7.

Intervention type: BEHAVIORAL
Intervention: Multisystemic therapy - intellectual disabilities
Description: Multisystemic therapy - intellectual disabilities (MST-ID) is a specialisation of standard MST (see above), tailored to the needs and skill deficits of families in which the adolescent and/or parent(s) has/have a known or suspected ID. In MST-ID, among others, simplified language and visual support are used, and extra attention is paid to the generalisation of what has been learned in the treatment sessions.
Study: NCT05168683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Each ALLN-346 treatment will be radiolabelled to contain 4 MBq 99mTc at time of dosing with light meal
Description: Dosing or radiolabelled ALLN-346 fast or slow release tablets or capsules. Scintigraphic images will be taken

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Each ALLN-346 treatment will be radiolabelled to contain 4 MBq 99mTc at time of dosing in fasted/fed state
Description: Selected dosing of Part One treatments in fasted and/or fed states
Study: NCT06323148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Adjuvant osimertinib for three years after radical surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: No adjuvant therapy
Description: No adjuvant therapy
Study: NCT06390696

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Children in placebo arm receive an indoor sandbox containing visually similar play sand modified with peat with low microbial diversity. Families also receive an indoor cultivation set including growing box, seeds, spray bottle, plant lamp and growing medium containing peat, inorganic fertilizers, and potting gravel with low microbial diversity.
Study: NCT06505018

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cureety techcare
Description: Each week, patients complete a questionnaire via the Cureety platform, specifically designed for the drug class or specific treatment being administered. Based on their responses, the Cureety TechCare algorithm classifies patients into one of four risk categories: correct (green), compromised (yellow), state to be monitored (orange), or critical state (red). (Note: the color code is not visible to the patient).~The medical team uses the dashboard for daily patient monitoring and manages alerts related to the clinical classification of the patient's condition. The physician in charge of telemonitoring interprets the data, adjusts the treatment as needed, and provides supportive care during standard care consultations. Patients are also notified of alerts with tailored messages guiding them on the actions to take according to the category determined by the device.
Study: NCT06484257

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Myopia
Description: Participants in this arm would receive progressive addition lenses specifically designed to correct myopia. These lenses would typically have a prescription for correcting nearsightedness (myopia) in addition to any other vision corrections needed, such as astigmatism correction and presbyopia. The participants would wear these lenses while using computers according to the study protocol.

Intervention type: OTHER
Group type: OTHER
Intervention: Hypermetropia
Description: Participants in this arm would receive progressive addition lenses specifically designed to correct hypermetropia. These lenses would typically have a prescription for correcting farsightedness (hypermetropia) in addition to any other vision corrections needed, such as astigmatism correction and presbyopia. The participants would wear these lenses while using computers according to the study protocol.
Study: NCT05398211

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preferred Recorded Music (PRM)
Description: Preferred Recorded Music (PRM) involves a credentialed music therapist in planning and administering, which qualifies it as music therapy, which is defined as a professional use of music and its elements to improve physical, social, communicative, emotional, intellectual, and spiritual health, optimize quality of life and wellbeing(Aigen, 2013; Bruscia, 2014). PRM intervention will be delivered for 30 minutes, once per day at the same time of the day, for three consecutive days. The intervention will consist of the previously assessed preferred songs/musical pieces. During the PRM intervention the MT will start/stop the music and otherwise not engage with the participants during the listening session.
Study: NCT05964530

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgery procedures include LAR+ anal preservation or APR

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery procedures include LAR+ anal preservation or APR
Study: NCT05526664

Intervention type: OTHER
Intervention: Genetic testing and Omics analysis
Description: Blood sample for genetic analysis and for Omics analysis as metabolomics and transcriptomics

Intervention type: OTHER
Intervention: Genetic testing and Omics analysis
Description: Blood sample for genetic analysis and for Omics analysis as metabolomics and transcriptomics

Intervention type: OTHER
Intervention: Genetic testing and Omics analysis
Description: Blood sample for genetic analysis and for Omics analysis as metabolomics and transcriptomics
Study: NCT05925452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GenaKumab
Description: GenaKumab 3.0mg/kg dose group : GenaKumab 3.0 mg/kg, Subcutaneous injection, Q4w； GenaKumab 4.0 mg/kg dose group : GenaKumab 4.0 mg/kg, Subcutaneous injection, Q4w
Study: NCT05386550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xevinapant (Debio 1143)
Description: Participants will receive 3 cycles of oral solution of Xevinapant (Debio 1143) at a dose of 200 milligrams per day (mg/day) once daily from Day 1 to 14, per 3-week cycle in combination with radiotherapy followed by 3 cycles of monotherapy of Xevinapant (Debio 1143) at a dose of 200 mg/day from Day 1 to 14, per 3-week cycle (Each cycle is of 3 weeks).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Participants will receive 66 Gy of intensity modulated radiation therapy (IMRT) in 33 fractions, 2 Gy/fraction, 5 days/week.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: IMRT
Description: Participants will receive 66 Gy of intensity modulated radiation therapy (IMRT) in 33 fractions, 2 Gy/fraction, 5 days/week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive 3 cycles of oral solution of placebo matched to Xevinapant (Debio 1143) once daily from Day 1 to 14 per 3-week cycle in combination with radiotherapy followed by 3 cycles of monotherapy of placebo matched to Xevinapant (Debio 1143) from Day 1 to 14, per 3-week cycle (Each cycle is of 3 weeks).
Study: NCT05638334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-S095012 tracer and S095012 will be administered via an IV infusion
Description: Imaging period 1 (Part A and Part B): The tracer will be administered with S095012 at non-therapeutic mass dose. The optimal mass dose of S095012 will be investigated in part A, and used in part B.~Treatment period (Part A to C): S095012 will be administered with multiple 28 days- cycles in a Q2W schedule.~Imaging period 2 (Part C): A second tracer dose will be administered at 1st treatment dose of S095012 in part C.
Study: NCT05156840

Intervention type: BEHAVIORAL
Intervention: Telehealth follow-up
Description: A telehealth follow-up visit will be conducted via the Epic electronic medical record with a pediatric hospitalist following hospital discharge.
Study: NCT05978492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TXN10128
Description: Participants receive TXN10128 capsules orally once daily.
Study: NCT04271748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time Restricted Feeding
Description: The counseling on the regimen will involve instructing the subjects on study compliance and fasting times. Subjects will be instructed to choose an eight-hour eating window (e.g., 11:00am - 7:00pm) during which the patient will be able to eat his/her normal diet. During the 16-hour fasting window (e.g., 7:00pm - 11:00am), the participant will be able to drink regular water and black coffee.
Study: NCT05398211

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preferred Live Music (PLM)
Description: Preferred Live Music (PLM) involves a credentialed music therapist in planning and administering which qualifies it as music therapy, which is defined as professional use of music and its elements to improve physical, social, communicative, emotional, intellectual and spiritual health, optimize quality of life and wellbeing (Aigen, 2013; Bruscia, 2014).PRM intervention will be delivered for 30 minutes, once per day at the same time of the day, for three consecutive days. The intervention will consist of the previously assessed preferred songs/musical pieces. The MT will be more actively engaged in a musical interaction with the participants in the PLM interventions.
Study: NCT06023823

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Toe spread out
Description: toe-spread-out exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling+Toe spread out
Description: The group will be given 3 sessions of dry needling with Seirin branded 0.6\*50 mm acupuncture needles for trigger pointe in the abductor hallucis muscle and additionally toe-spread-out exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling+Toe spread out
Description: The group will be given 3 sessions of dry needling with Seirin branded 0.6\*50 mm acupuncture needles for trigger pointe in the abductor hallucis muscle and additionally toe-spread-out exercise.
Study: NCT05931159

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal Hypopressive Training
Description: Week 1 and 2 - Patient education , Hypopressive Maneuvers in Standing, Sitting and Supine 5-7 repetitions x 5 sets, with a 10-second hold each time, rest for 30 seconds between each set, 2 days/week.~Week 3 and 4, Hypopressive breathing in with varying arm movements along with Week 1 and 2 protocols.~Week 5 to 8 - Hypopressive breathing in kneeling, Four-point kneeling and sitting, and supine positions with varying arm movements 5-7 repetitions x 5 sets, with a 10-second hold each time, rest for 30 seconds between each set, 2 days/week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical therapy for DrA
Description: Week 1 to 4, Draw-in maneuver in supine, Quadruped and Prone lying, Bent knee Fallouts and Curl ups. (8 to 12 repetitions x 3 sets, 2 days/week)~Week 5 to 8, Front and side planks added to week 1 to 4 exercises. (12 to 20 repetitions x e sets, 2 days/week)
Study: NCT05668455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: 1 drops 4 times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 1 drops 4 times a day
Study: NCT05051631

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention plus 12 months maintenance
Description: The intervention will include 2 months of data collection in the control period, 4 months of education and awareness training, and 12 months of data collection in the maintenance time period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention plus 10 months maintenance
Description: The intervention will include 4 months of data collection in the control period, 4 months of education and awareness training, and 10 months of data collection in the maintenance time period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention plus 8 months maintenance
Description: The intervention will include 6 months of data collection in the control period, 4 months of education and awareness training, and 8 months of data collection in the maintenance time period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention plus 6 months maintenance
Description: The intervention will include 8 months of data collection in the control period, 4 months of education and awareness training, and 6 months of data collection in the maintenance time period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention plus 4 months maintenance
Description: The intervention will include 10 months of data collection in the control period, 4 months of education and awareness training, and 4 months of data collection in the maintenance time period.
Study: NCT05668455

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Povidone
Description: 1 drops 4 times a day
Study: NCT06140498

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Efficacy Training and Ecological Momentary Assessment
Description: Participants receive 3 self-efficacy trainings per day, combined with Ecological Momentary Assessments assessing mood, social contacts, and virtual context 3x/day for one week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention: Ecological Momentary Assessment only
Description: Participants receive Ecological Momentary Assessments assessing mood, social contacts, and virtual context 3x/day for one week only
Study: NCT04752566

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Eculizumab will be administered via IV infusion once a week for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered via IV infusion once a week for 4 weeks.
Study: NCT06130774

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Retro walking and conventional
Description: Patient will start retro walking with first he/she will raise his/her one foot with toe off first then heel will be off from ground. swing phase of same leg would be done in backward direction with flexion on knee and extension will be performed on hip. Then patient will place the same foot on ground behind the other foot, with toe touch first on ground, and so this way patient would continue his retro-walk for 20 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: Hot pack in supine lying (10min) TENS (10min ) Tibiofemoral mobilization (grade 1,2 ,3) (10rep) Static quadriceps exercise in supine (10rep x 3sec x2set) hip abduction in side lying(10repx 2set) knee bending exercise in prone lying ( 10rep x 2set) Hamstring stretch in supine ( 10 rep x 2 set)
Study: NCT05369520

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TESCoN device - Thoracic stimulation
Description: TCSCS will be delivered using a non-invasive central nervous system stimulator (TESCoN, SpineX Inc., CA, USA). The stimulation site will be over the thoracic spinal cord (T7-T12, Group 1).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TESCoN device - Lumbosacral stimulation
Description: TCSCS will be delivered using a non-invasive central nervous system stimulator (TESCoN, SpineX Inc., CA, USA). The stimulation site will be over the lumbosacral spinal cord (L1 - L3, Group 2).
Study: NCT05864365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATH434
Description: ATH434 taken by mouth two times per day
Study: NCT05576714

Intervention type: OTHER
Intervention: delineate its prognostic biomarker, host genetic factors, immunopathogenesis and viral pathogenesis
Description: We will delineate the clinical and laboratory characteristics of COVID-19 associated encephalopathy and encephalitis, the role of immune, virology, genetics mechanism in pathophysiology, and will optimize the treatment algorithm based on the result of this study. We also expect that the important biomarkers and risk factors associated with clinical outcome and severity, the immunopathogenesis of MIS-C, host genetic factors and the viral pathogenesis and microbiota associated with MIS-C will be found.
Study: NCT06492148

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial Release
Description: The myofascial release technique is a widely used manual therapy method characterized by low-load, prolonged mechanical forces applied to manipulate the myofascial complex, aiming to restore optimal length, alleviate pain, and improve function.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham-Myofascial Release
Description: The hands of the researcher applying the technique will be placed in the same areas as the myofascial release technique, with only the palms in light contact for the same duration. However, no intervention will be made to create any pressure or open the tissue barrier.
Study: NCT06352905

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV)
Description: WBV is a platform that vibrates while a person stands or sits and performs exercises. The WBV session will consist of 5 sets of 60 seconds set at 6 Hertz (frequency), 3 mm (amplitude) while performing mid-squats. There will be a 1 minute rest in between each set. These parameters were chosen as commonly used parameters in previous studies of WBV in people with PD.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Mid-squats performed on level ground 5 repetitions of 60 seconds with 1 minute rest in between each set.
Study: NCT06375278

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra-Ear Canal Cooling Catheter
Description: Mild therapeutic hypothermia will be applied via the catheter device installed inside the ear canal by an experienced surgeon during cochlear implantation (CI) surgery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra-Ear Canal Cooling Catheter
Description: Mild therapeutic hypothermia will be applied via the catheter device installed inside the ear canal by an experienced surgeon during cochlear implantation (CI) surgery.
Study: NCT05362591

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: resin bonded bridge with no preparation
Description: resin bonded bridge without enamel preparation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: resin bonded bridge with minimal preparation
Description: resin bonded bridge with minimal preparation of tooth enamel
Study: NCT05576714

Intervention type: OTHER
Intervention: delineate its prognostic biomarker, host genetic factors, immunopathogenesis and viral pathogenesis
Description: We will delineate the clinical and laboratory characteristics of COVID-19 associated encephalopathy and encephalitis, the role of immune, virology, genetics mechanism in pathophysiology, and will optimize the treatment algorithm based on the result of this study. We also expect that the important biomarkers and risk factors associated with clinical outcome and severity, the immunopathogenesis of MIS-C, host genetic factors and the viral pathogenesis and microbiota associated with MIS-C will be found.

Intervention type: OTHER
Intervention: delineate its prognostic biomarker, host genetic factors, immunopathogenesis and viral pathogenesis
Description: We will delineate the clinical and laboratory characteristics of COVID-19 associated encephalopathy and encephalitis, the role of immune, virology, genetics mechanism in pathophysiology, and will optimize the treatment algorithm based on the result of this study. We also expect that the important biomarkers and risk factors associated with clinical outcome and severity, the immunopathogenesis of MIS-C, host genetic factors and the viral pathogenesis and microbiota associated with MIS-C will be found.
Study: NCT06500559

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP injection
Description: PRP (0.7 ml = 70 unit) will be injected submucosal disto-buccal and disto-palatal to the maxillary canine like the local anesthesia injection in group I experimental sides

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined decortication and PRP injection
Description: Experimental sides will receive PRP injection after performing decortication. After administration of local anesthesia, two-line flap will be performed from the mesial surface of the maxillary second premolar to the distal surface of the maxillary canine Mucoperiosteal flap will be reflected in the buccal side. Two millimeters of marginal crestal bone will be held intact and using a high-speed drill and a round carbide bur (1mm diameter) under copious saline irrigation, the cortical wall will be penetrated to reach marrow spaces. Multiple perforations (10 holes for standardization) in the cortical bone will be created. The surgical site will then rinsed, and the flap will be repositioned and sutured.